Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance-Guided Therapy?
Abstract
Background: We assessed trends in moxifloxacin use and efficacy for Mycoplasma genitalium over a decade at Melbourne Sexual Health Centre (MSHC). Specific M. genitalium mutations, namely ParC-S83I, have been associated with moxifloxacin failure. In 2024 MSHC introduced ParC-S83 testing, recommending moxifloxacin for ParC-S83 wild type infections and alternative regimens if the ParC-S83I mutation was detected. We present preliminary impacts of ParC-S83 testing on moxifloxacin use and efficacy.
Methods: Clients with M. genitalium from 2015 to 2024 were treated with doxycycline preceding macrolide resistance-guided azithromycin or moxifloxacin. Clients with a test of cure 14-90 days after completing moxifloxacin who reported > 50% adherence and no condomless sex prior to test of cure were eligible for efficacy analyses. Proportions with 95% CIs were calculated for moxifloxacin use and efficacy, with trends assessed by logistic regression. Moxifloxacin use and efficacy were compared in the 12 months before and after introduction of the ParC-S83 assay.
Results: From 2015 to 2024, 2611 of 5739 M. genitalium infections received moxifloxacin. Moxifloxacin use increased from 6.7% (n = 19/282; 95% CI, 4.1%-10.3%) in 2015 to 60.3% (n = 482/800; 95% CI, 56.8%-63.7%) in 2023 (Ptrend < .0001). Efficacy analyses included 1623 infections. Moxifloxacin efficacy decreased from 100% (n = 11/11) in 2015 to 79.3% (n = 238/300; 95% CI, 74.3%-83.8%) in 2023 (Ptrend = .007). After introduction of…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.